Schizophrenia drug Cobenfy could treat Alzheimer’s

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023.  Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue. In…

Read More

JPMorgan Chase (JPM) earnings Q4 2024

CEO of Chase Jamie Dimon looks on as he attends the seventh “Choose France Summit”, aiming to attract foreign investors to the country, at the Chateau de Versailles, outside Paris, on May 13, 2024. Lucovic Marin | Getty Images JPMorgan Chase is scheduled to report fourth-quarter earnings before the opening bell Wednesday. Here’s what Wall…

Read More

Goldman Sachs (GS) earnings Q4 2024

David Solomon, Chairman & CEO Goldman Sachs, speaking on CNBC’s Squawk Box at the World Economic Forum Annual Meeting in Davos, Switzerland on Jan. 17th, 2024. Adam Galici | CNBC Goldman Sachs is scheduled to report fourth-quarter earnings before the opening bell Wednesday. Here’s what Wall Street expects: Earnings: $8.22 per share, according to LSEG…

Read More

Stocks making the biggest moves midday: NVDA, RGTI, MRNA

Check out the companies making headlines in midday trading: Quantum stocks — Quantum computing stocks dropped after Meta Platforms CEO Mark Zuckerberg became the latest high-profile executive to ease expectations for the technology. Rigetti Computing dropped 27%, while D-Wave Quantum shed 32%. The Defiance Quantum ETF lost 2.5%. Nvidia , chip stocks — Popular semiconductor…

Read More